English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Meningiomas represent the most frequently diagnosed intracranial tumors. Inflammation and immune processes may play an important role in therapeutic response as well as in anti- and pro-tumor modulating function. In tumors, inflammatory markers have been able to provide useful prognostic information for treatment or clinical evaluation of patients. The aim of this study was to investigate preoperative hematological markers concerning recurrence or regrowth and clinical variables in meningioma. Eighty nine patients with no corticosteroid therapy were included. Blood tests and tumor characteristics were collected from medical records. Recurrence-free survival was evaluated using Cox regression and Kaplan-Meier curves. Of the 89 cases, 73 (82%) were grade I and 16 (18%) grade II. The mean age was 53±13.9 years, with higher frequency in women, 2:1 proportion. The most frequent subtypes were meningothelial (40.4%), transitional (23.5%) and atypical (17.9%), 64% with peripheral location and 64% had a size greater than 3 cm. Regarding tumor resection, 49 (55.1%) underwent complete surgery (40 remained with tumor (81.6%) and 9 relapse (18.3%)) and 40 (44.9%) submitted to partial resection surgery (29 remained with persistent lesion (72.5%) and 11 regrowth (25%)). In total, 20 (22.4%) cases of recurrence or regrowth were observed. The median recurrence-regrowth free survival (RFS) was 62 months, 96.1% at 1 year, 67.4% at 3 years and 51.2% at 5 years. In univariate analysis, anemia (p=0.04), neutrophilia (p=0.02) and neutrophilis/lymphocyts ratio (NLR) (p=0.03) were associated with an increased risk of recurrence or regrowth and poor RFS. In multivariate, the interaction between anemia and NLR &amp;gt;4 represented a higher risk of recurrence or regrowth (p=0.003). The preoperative presence of anemia, neutrophilia, and NLR was associated with an increased risk of recurrence or regrowth in meningiomas, emphasizing the importance of preoperative evaluation of these parameters.

SUN-130 Preoperative Hematological Parameters Associated with Recurrence or Regrowth of Meningiomas